Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Dermatol Ther (Heidelb). 2024 Jan;14(1):183-185. doi: 10.1007/s13555-023-01076-x.
No abstract available

Publication types

  • Published Erratum